153 related articles for article (PubMed ID: 26150116)
1. Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies.
Gasmi H; Danede F; Siepmann J; Siepmann F
J Control Release; 2015 Sep; 213():120-127. PubMed ID: 26150116
[TBL] [Abstract][Full Text] [Related]
2. Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems.
Gasmi H; Siepmann F; Hamoudi MC; Danede F; Verin J; Willart JF; Siepmann J
Int J Pharm; 2016 Nov; 514(1):189-199. PubMed ID: 27543353
[TBL] [Abstract][Full Text] [Related]
3. Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics.
Gabor F; Ertl B; Wirth M; Mallinger R
J Microencapsul; 1999; 16(1):1-12. PubMed ID: 9972498
[TBL] [Abstract][Full Text] [Related]
4. Long-term controlled release of PLGA microparticles containing antidepressant mirtazapine.
Vysloužil J; Doležel P; Kejdušová M; Košťál V; Beneš L; Dvořáčková K
Pharm Dev Technol; 2016 Mar; 21(2):214-21. PubMed ID: 25495857
[TBL] [Abstract][Full Text] [Related]
5. Drug release from PLGA-based microparticles: effects of the "microparticle:bulk fluid" ratio.
Klose D; Siepmann F; Willart JF; Descamps M; Siepmann J
Int J Pharm; 2010 Jan; 383(1-2):123-31. PubMed ID: 19748558
[TBL] [Abstract][Full Text] [Related]
6. Quantifying drug release from PLGA nanoparticulates.
Corrigan OI; Li X
Eur J Pharm Sci; 2009 Jun; 37(3-4):477-85. PubMed ID: 19379812
[TBL] [Abstract][Full Text] [Related]
7. Design and development of a novel controlled release PLGA alginate-pectinate polyspheric drug delivery system.
Sweet JL; Pillay V; Choonara YE
Drug Deliv; 2007 Jul; 14(5):309-18. PubMed ID: 17613019
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures.
Tamani F; Bassand C; Hamoudi MC; Siepmann F; Siepmann J
Int J Pharm; 2021 Mar; 596():120220. PubMed ID: 33486018
[TBL] [Abstract][Full Text] [Related]
9. Compressed biodegradable matrices of spray-dried PLGA microspheres for the modified release of ketoprofen.
Gavini E; Sanna V; Juliano C; Giunchedi P
J Microencapsul; 2003; 20(2):193-201. PubMed ID: 12554374
[TBL] [Abstract][Full Text] [Related]
10. Seeing is believing, PLGA microsphere degradation revealed in PLGA microsphere/PVA hydrogel composites.
Gu B; Sun X; Papadimitrakopoulos F; Burgess DJ
J Control Release; 2016 Apr; 228():170-178. PubMed ID: 26965956
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Diprophylline dispersions.
Tamani F; Bassand C; Hamoudi MC; Danede F; Willart JF; Siepmann F; Siepmann J
Int J Pharm; 2019 Dec; 572():118819. PubMed ID: 31726196
[TBL] [Abstract][Full Text] [Related]
12. Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis.
Thi THH; Priemel PA; Karrout Y; Driss V; Delbeke M; Dendooven A; Flament MP; Capron M; Siepmann J
Int J Pharm; 2017 Nov; 533(1):26-33. PubMed ID: 28923765
[TBL] [Abstract][Full Text] [Related]
13. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
Klose D; Delplace C; Siepmann J
Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
[TBL] [Abstract][Full Text] [Related]
14. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
[TBL] [Abstract][Full Text] [Related]
15. Issues in long-term protein delivery using biodegradable microparticles.
Ye M; Kim S; Park K
J Control Release; 2010 Sep; 146(2):241-60. PubMed ID: 20493221
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro.
Fernández-Carballido A; Herrero-Vanrell R; Molina-Martínez IT; Pastoriza P
Int J Pharm; 2004 Jul; 279(1-2):33-41. PubMed ID: 15234792
[TBL] [Abstract][Full Text] [Related]
17. How porosity and size affect the drug release mechanisms from PLGA-based microparticles.
Klose D; Siepmann F; Elkharraz K; Krenzlin S; Siepmann J
Int J Pharm; 2006 May; 314(2):198-206. PubMed ID: 16504431
[TBL] [Abstract][Full Text] [Related]
18. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
Faisant N; Akiki J; Siepmann F; Benoit JP; Siepmann J
Int J Pharm; 2006 May; 314(2):189-97. PubMed ID: 16510257
[TBL] [Abstract][Full Text] [Related]
19. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
20. Enhanced gentamicin loading and release of PLGA and PLHMGA microspheres by varying the formulation parameters.
Chaisri W; Ghassemi AH; Hennink WE; Okonogi S
Colloids Surf B Biointerfaces; 2011 Jun; 84(2):508-14. PubMed ID: 21353499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
